Jillian Marianos
Family · Washington, DCNPI 1275266876
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,111 of the $4,055 with a category attached, or 76.7%. 22 manufacturers reported payments, led by Medtronic at 44.7% of the total. Reporting peaked in 2024 at $2,223 and has fallen 86.5% since, to $301 in 2025. Among family clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $33.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Pfizer$218
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$187
- Boehringer Ingelheim$178
- Scpharmaceuticals Inc.$171
- Johnson & Johnson$155
- plus $1K from 16 others
What the payments were for
- Travel & lodging$86621%
- Food & beverage$3,11177%
- Education$782%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 37 | $1,814 |
| Pfizer | 11 | $218 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $187 |
| Boehringer Ingelheim | 8 | $178 |
| Scpharmaceuticals Inc. | 4 | $171 |
| Johnson & Johnson | 8 | $155 |
| Boston Scientific | 5 | $138 |
| Abiomed | 1 | $135 |
| E.r. Squibb & Sons, L.L.C. | 5 | $127 |
| Cardiva Medical, Inc. | 2 | $120 |
| Alnylam Pharmaceuticals Inc. | 1 | $120 |
| Actelion Pharmaceuticals US, Inc. | 2 | $117 |
| Novartis | 5 | $113 |
| Merck | 5 | $97 |
| AstraZeneca(2 entities) | 4 | $77 |
| Baxter Healthcare | 1 | $67 |
| Amgen | 3 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $58 |
| Novo Nordisk | 2 | $40 |
| Kerecis Limited | 1 | $28 |
| Impulse Dynamics (USA) Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$1,035
- Impella$135
- ONPATTRO$120
- FUROSCIX$116
How this compares
$4,055 in reported general payments places this provider in the 90th percentile of 392 family providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 137 | $210,120 |
| JardianceEmpagliflozin | 65 | $92,507 |
| EntrestoSacubitril/Valsartan | 48 | $72,403 |
| XareltoRivaroxaban | 42 | $48,044 |
| BrilintaTicagrelor | 17 | $13,409 |
| Metoprolol Succinate | 206 | $3,551 |
| Atorvastatin Calcium | 167 | $1,669 |
| Ezetimibe | 50 | $1,314 |
| Rosuvastatin Calcium | 83 | $1,285 |
| ClopidogrelClopidogrel Bisulfate | 77 | $1,152 |
| Amlodipine Besylate | 127 | $1,110 |
| Amiodarone Hcl | 21 | $1,074 |
| Losartan Potassium | 116 | $1,029 |
| Nifedipine ErNifedipine | 30 | $919 |
| Carvedilol | 112 | $817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $218 | $210,120137 claims |
| Boehringer IngelheimJardiance | $178 | $92,50765 claims |
| NovartisEntresto | $113 | $72,40348 claims |
| Johnson & JohnsonXarelto | $155 | $48,04442 claims |
| AstraZenecaBrilinta | $77 | $13,40917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 392 family providers in District of Columbia.
Other family in Washington
- Amy StewartWashington$489K
- Kara CouchWashington$144K
- Laura XandersWashington$109K
- Laura MackeWashington$39K
- Cassandra ThompsonWashington$11K
- Sharmin DiazWashington$9K
- Emily BertrandWashington$8K
- Ana Carrion-GelabertWashington$7K
- Chanda CopelandWashington$7K
- Suad NsouliWashington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.